Altimmune, Inc.
ALTNasdaq
$2.87
↑ +0.7%Jul 17 close · end-of-day
Price
1Y↓ -31.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$357.2M
Enterprise Value
$60.2M
P/E
—
P/S
—
P/B
1.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$91.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-32.1%
ROIC
—
Debt / Equity
0.1
Net Cash
$297.0M
Return 1Y
-29.1%
Company profile
Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
- CEO
- Vipin K. Garg
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- Maryland
- Website
- altimmune.com
Management & directors
- Durso Jerome BenedictPresident and CEO
- Weaver Gregory LChief Financial Officer
- Roberts M ScotChief Scientific Officer
- Jordt Raymond MChief Business Officer
- Harris Matthew ScottChief Medical Officer
Roles derived from SEC Form 4 filings.
Earnings
ALT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.18↓ -30.8%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.2M | $4.4M | -$68,000.00 | $426,000.00 | $20,000.00 | $41,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$54.8M | -$96.9M | -$87.7M | -$95.9M | -$103.2M | -$94.5M |
| Net income | -$49.0M | -$97.1M | -$84.7M | -$88.4M | -$95.1M | -$88.1M |
| Diluted EPS | -$1.91 | -$2.35 | -$1.81 | -$1.66 | -$1.34 | -$1.00 |
| Operating cash flow | -$34.3M | -$78.2M | -$62.6M | -$75.8M | -$79.8M | -$67.5M |
| Free cash flow | -$34.5M | -$90.4M | -$62.7M | -$75.9M | — | -$67.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -669.5% | -2197.6% | 129029.4% | -22518.5% | -515860.0% | -230461.0% |
| Net margin | -599.2% | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5,000.00 | $5,000.00 | $5,000.00 | $5,000.00 | $5,000.00 | $5,000.00 | $26,000.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$26.7M | -$24.8M | -$24.9M | -$21.8M | -$22.9M | -$20.9M | -$28.9M | -$24.2M |
| Net income | -$24.6M | -$22.8M | -$23.2M | -$19.6M | -$22.1M | -$19.0M | -$27.4M | -$22.6M |
| Diluted EPS | -$0.35 | -$0.32 | -$0.33 | -$0.26 | -$0.27 | -$0.21 | -$0.26 | -$0.18 |
| Operating cash flow | -$18.1M | -$27.1M | -$18.3M | -$16.8M | -$19.4M | -$11.9M | -$19.4M | -$20.9M |
| Free cash flow | — | — | — | — | — | -$11.9M | — | -$21.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -534900.0% | -495340.0% | -497320.0% | -436300.0% | -458440.0% | -417180.0% | -111126.9% | — |
| Net margin | -492800.0% | -456900.0% | -463600.0% | -391500.0% | -442920.0% | -380280.0% | -105223.1% | — |
Company news
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-04-06 | GILL JOHN | Buy | 9,200 | $3.41 | $31,349.92 | filing |
| 2026-04-01 | Durso Jerome Benedict· President and CEO | Buy | 15,000 | $3.14 | $47,100.00 | filing |
| 2026-04-01 | WEAVER GREGORY L· Chief Financial Officer | Buy | 10,000 | $3.15 | $31,499.00 | filing |
| 2026-03-06 | Durso Jerome Benedict· President and CEO | Buy | 20,000 | $3.54 | $70,790.00 | filing |
| 2026-03-06 | WEAVER GREGORY L· Chief Financial Officer | Buy | 5,000 | $3.54 | $17,700.00 | filing |
| 2026-02-02 | Roberts M Scot· Chief Scientific Officer | Tax withholding | 2,329 | $5.55 | $12,925.95 | filing |
| 2026-02-02 | Roberts M Scot· Chief Scientific Officer | Option exercise | 7,775 | $0.00 | $0.00 | filing |
| 2026-01-31 | Garg Vipin K | Award | 6,926 | $3.07 | $21,262.82 | filing |
| 2026-01-31 | Roberts M Scot· Chief Scientific Officer | Award | 5,567 | $3.07 | $17,090.69 | filing |
| 2026-01-31 | Jordt Raymond M· Chief Business Officer | Award | 4,571 | $3.07 | $14,032.97 | filing |
| 2026-01-30 | Garg Vipin K | Tax withholding | 11,632 | $5.60 | $65,139.20 | filing |
| 2026-01-30 | Roberts M Scot· Chief Scientific Officer | Tax withholding | 2,859 | $5.60 | $16,010.40 | filing |
| 2026-01-30 | Garg Vipin K | Option exercise | 26,775 | $0.00 | $0.00 | filing |
| 2026-01-30 | Roberts M Scot· Chief Scientific Officer | Option exercise | 9,275 | $0.00 | $0.00 | filing |
| 2026-01-27 | Garg Vipin K | Tax withholding | 17,898 | $6.18 | $110,609.64 | filing |
| 2026-01-27 | Roberts M Scot· Chief Scientific Officer | Tax withholding | 4,748 | $6.18 | $29,342.64 | filing |
| 2026-01-27 | Jordt Raymond M· Chief Business Officer | Tax withholding | 4,229 | $6.18 | $26,135.22 | filing |
| 2026-01-27 | Roberts M Scot· Chief Scientific Officer | Option exercise | 15,850 | $0.00 | $0.00 | filing |
| 2026-01-27 | Jordt Raymond M· Chief Business Officer | Option exercise | 15,850 | $0.00 | $0.00 | filing |
| 2026-01-27 | Garg Vipin K | Option exercise | 41,200 | $0.00 | $0.00 | filing |
| 2026-01-25 | Garg Vipin K | Tax withholding | 17,984 | $5.50 | $98,912.00 | filing |
| 2026-01-25 | Roberts M Scot· Chief Scientific Officer | Tax withholding | 4,373 | $5.50 | $24,051.50 | filing |
| 2026-01-25 | Jordt Raymond M· Chief Business Officer | Tax withholding | 3,855 | $5.50 | $21,202.50 | filing |
| 2026-01-25 | Jordt Raymond M· Chief Business Officer | Option exercise | 14,600 | $0.00 | $0.00 | filing |
| 2026-01-25 | Garg Vipin K | Option exercise | 42,050 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.